 |
市場調查報告書
商品編碼
1122335
ANCA 相關血管炎藥物市場：按類型、藥物類型、分銷渠道、地區 - 規模、份額、前景、機會分析，2022-2030ANCA Vasculitis Drug Market, by Type, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030 |
||||||
抗中性粒細胞胞質自身抗體 (ANCA) 相關性血管炎 (AAV) 是一組以小血管炎症和損傷為特徵的自身免疫性疾病。一種稱為 ANCA 的自身反應性抗體負責這種炎症，因為它與中性粒細胞結合併過度激活。這種免疫系統故障是由遺傳和環境因素引起的。根據受影響的器官或身體部位，ANCA 血管炎會引起各種症狀。例如，如果皮膚中的血管受損，可能會出現皮疹。此外，當腎臟的血管受損時，血液和蛋白質會滲入尿液，從而對腎臟造成損害。 ANCA 血管炎主要分為三種類型：顯微鏡下多血管炎（MPA）、肉芽腫性多血管炎（GPA）和嗜酸性肉芽腫性多血管炎（EGPA）。目前還沒有治愈這種疾病的方法，並給予治療來控制病情。患者通常分兩個階段接受治療：誘導症狀緩解的治療（誘導治療）和盡可能長時間維持緩解的治療（維持治療）。
市場動態
市場上的主要參與者專注於開展研發活動並在各種醫學會議上展示他們的研究成果，預計這將在預測期內推動市場增長。例如，2022 年 5 月，生物製藥公司 ChemoCentryx, Inc. 宣布了關鍵的 3 期 ADVOCATE 試驗結果，並宣布即將在三個主要醫學會議上發表演講，重點是調查糖皮質激素在 ANCA 相關血管炎中的使用負擔。會議：ATS 2022（美國胸科學會）2022 年 5 月 15 日至 17 日；舊金山，ISPOR 2022（國際藥學和結果學會）2022 年 5 月 15 日至 18 日；華盛頓，第 59 屆 ERA 會議（歐洲會議）5 月 19 日至 22 日， 2022，法國巴黎/虛擬
本研究的主要特點
- 本報告對全球 ANCA 血管炎藥物市場進行了深入分析，提供了以 2021 年為基準年的預測期間（2022-2030 年）的市場規模和復合年增長率 (CAGR%)。
- 解釋不同細分市場的潛在收入機會，並描述該市場具有吸引力的投資建議矩陣。
- 它還提供了有關市場驅動因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
- 根據公司亮點、產品組合、關鍵亮點、財務業績和戰略等參數，介紹了全球 ANCA 血管炎治療市場的主要參與者的概況。
- 本研究涵蓋的主要公司包括 ChemoCentryx, Inc.、Vifor Pharma、GlaxoSmithKline plc、Amgen、Genentech, Inc.、Pfizer Inc.、Biogen、InflaRx GmbH 和 AstraZeneca
- 本報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。我猜。
- 全球 ANCA 血管炎藥物市場報告迎合了該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和財務分析師。
- 利益相關者可以通過用於分析全球 ANCA 血管炎藥物市場的各種戰略矩陣來促進決策制定。
內容
第 1 章目的和先決條件
- 調查目的
- 先決條件
- 縮寫說明
第二章市場展望
- 舉報內容
- 市場定義和範圍
- 執行摘要
- 市場快照：按類型
- 按藥物類型劃分的市場概況
- 市場快照：按分銷渠道
- 市場概況，按國家/地區分類
- 連貫的機會圖 (COM)
第 3 章市場動態、法規和趨勢分析
- 市場動態
- 驅動程序
- 限制因素
- 市場機會
- 影響分析
- 市場趨勢
- 主要發展狀況
- 監管場景
- PEST 分析
- 流行病學
- 產品發布/批准
第 4 章 ANCA 相關血管炎治療藥物的全球市場 - 冠狀病毒 (COVID-19) 大流行的影響
- 經濟影響
- COVID-19 流行病學調查
- 供需分析
第 5 章 2017-2030 年按類型分列的 ANCA 相關血管炎藥物全球市場
- 肉芽腫性多血管炎 (GPA)
- 顯微鏡下多血管炎 (MPA)
- 肉芽腫伴嗜酸性多血管炎 (EGPA)
- 腎局限性血管炎
第 6 章全球 ANCA 相關血管炎藥物市場，按藥物類型，2017-2030 年
- 糖皮質激素
- 環磷□胺
- 利妥昔單抗
- 甲氨蝶呤
- 嗎替麥考酚酯
- 硫唑嘌呤
- 美泊利單抗
- 阿巴科麵包
- 其他
第 7 章全球 ANCA 相關血管炎治療市場，按分銷渠道，2017-2030 年
- 醫院藥房
- 零售藥房
- 在線藥店
第 8 章全球 ANCA 相關血管炎藥物市場：2017-2030 年按地區分列
- 北美
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲地區
- 歐洲
- 英國
- 德國
- 意大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲
- 亞太地區
- 中國
- 印度
- 日本
- 東盟
- 澳大利亞
- 韓國
- 其他亞太地區
- 中東
- 海合會
- 以色列
- 其他中東
- 非洲
- 北非
- 中非
- 南非
第 9 章競爭格局
- ChemoCentryx, Inc.
- Vifor Pharma
- GlaxoSmithKline plc
- Amgen
- Genentech, Inc.
- Pfizer Inc.
- Biogen
- InflaRx GmbH
- AstraZeneca
第 10 章
- 調查方法
- 關於出版商
Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a group of autoimmune diseases characterized by inflammation and damage to small blood vessels. Self-reactive antibodies known as ANCAs, which bind to and excessively activate neutrophils, are the cause behind this inflammation. This immune system malfunction is caused by hereditary and environmental factors. ANCA vasculitis can result in a variety of symptoms depending on the organ or body part affected. For instance, if the skin's blood vessels are harmed, a rash may result. Blood and protein leakage into the urine as well as kidney damage can result from problems with the blood vessels in the kidney. There are three main types of ANCA vasculitis, microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Currently, there is no cure for the disease and treatments are available to manage the condition. Patients normally undergo two phases of treatment, one designed to induce the remission of symptoms (induction treatment), and a second phase meant to keep patients in remission for as long as possible (maintenance treatment).
Market Dynamics
Key players in market are focused on carrying out research and development activities and demonstrating the results of the studies at various medical conferences, which is expected to drive the market growth over the forecast period. For instance, in May 2022, ChemoCentryx, Inc., a biopharmaceutical company, announced upcoming presentations at three key medical conferences that would highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of tavneos (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and research into the burden of glucocorticoid use in ANCA-associated vasculitis. The three conferences were ATS 2022 (American Thoracic Society), May 15-17, 2022, San Francisco, ISPOR 2022 (International Society for Pharmacoeconomics and Outcomes Research), May 15-18, 2022, Washington, and 59th ERA Conference (European Renal Association), May 19-22, 2022, Paris, France/Virtual
Key features of the study:
- This report provides in-depth analysis of the global ANCA vasculitis drug market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global ANCA vasculitis drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include ChemoCentryx, Inc., Vifor Pharma, GlaxoSmithKline plc, Amgen, Genentech, Inc., Pfizer Inc., Biogen, InflaRx GmbH, and AstraZeneca
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global ANCA vasculitis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ANCA vasculitis drug market
Detailed Segmentation:
- Global ANCA Vasculitis Drug Market, By Type:
- Granulomatosis with Polyangiitis (GPA)
- Microscopic Polyangiitis (MPA)
- Eosinophilic Granulomatosis with Polyangiitis (EGPA)
- Renal-limited Vasculitis
- Global ANCA Vasculitis Drug Market, By Drug Type:
- Glucocorticoids
- Cyclophosphamide
- Rituximab
- Methotrexate
- Mycophenolate mofetil
- Azathioprine
- Mepolizumab
- Avacopan
- Others
- Global ANCA Vasculitis Drug Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global ANCA Vasculitis Drug Market, By Region:
- North America
- By Country
- U.S.
- Canada
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Region/Country
- South Africa
- Central Africa
- North Africa
- North America
- Company Profiles
- ChemoCentryx, Inc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Vifor Pharma
- GlaxoSmithKline plc
- Amgen
- Genentech, Inc.
- Pfizer Inc.
- Biogen
- InflaRx GmbH
- AstraZeneca
- ChemoCentryx, Inc.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Country
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- PEST Analysis
- Epidemiology
- Product Launch/Approvals
4. Global ANCA Vasculitis Drug Market- Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- COVID-19 Epidemiology
- Demand and Supply Analysis
5. Global ANCA Vasculitis Drug Market, By Type, 2017 - 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Granulomatosis with Polyangiitis (GPA)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Microscopic Polyangiitis (MPA)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Eosinophilic Granulomatosis with Polyangiitis (EGPA)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Renal-limited Vasculitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
6. Global ANCA Vasculitis Drug Market, By Drug Type, 2017 - 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Glucocorticoids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Cyclophosphamide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Rituximab
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Methotrexate
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Mycophenolate mofetil
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Azathioprine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Mepolizumab
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Avacopan
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
7. Global ANCA Vasculitis Drug Market, By Distribution Channel, 2017 - 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
8. Global ANCA Vasculitis Drug Market, By Region, 2017 - 2030, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- ChemoCentryx, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Vifor Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Genentech, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Biogen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- InflaRx GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Section
- Research Methodology
- About Us
